CONTENTS

9 Chapter 1 General introduction

21 Chapter 2a Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up

37 Chapter 2b Anti-adalimumab antibodies and adalimumab drug concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up

49 Chapter 3 Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up

61 Chapter 4 Golimumab trough levels, anti-drug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice

69 Chapter 5 Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study

87 Chapter 6 Comparing tapering strategy to standard dosing regimen of Tumor Necrosis Factor inhibitors in patients with spondyloarthritis in low disease activity

105 Chapter 7 Dried blood spots obtained by finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab antibodies in patients with rheumatic inflammatory diseases

131 Chapter 8 Discussion and summary

147 Appendix

149 Nederlandse samenvatting

155 Dankwoord

157 List of publications

159 Curriculum Vitae